Tirzepatide, semaglutide, and liraglutide lead to weight loss in adults with obesity and T1D over 1 year; the greatest weight loss and a modest decrease in A1c levels are seen with tirzepatide.

WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological effects, according to a post-hoc analysis of the phase III ESSENCE trial.

This article was reviewed by Lynn Marie Morski, MD, JD. Does Ozempic® Lower Blood Pressure? Key Takeaways: Ozempic® may lower blood pressure. Semaglutide — the active

About semaglutide 2.4 mg in metabolic dysfunction-associated steatohepatitis (MASH)

GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met efficacy benchmarks, with gastrointestinal side effects common but serious adverse events similar to placebo.

One study found that semaglutide helps to improve liver health in people with metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease. The use of semaglutide, a medication from the class of GLP-1 receptor agonists, has ...

Both semaglutide and tirzepatide are associated with improvements in quality of life for adults with obesity, though tirzepatide outperformed semaglutide for adults with limited physical function, study data revealed.